Evaluation of the prophylaxis and treatment of COVID-associated coagulopathy
Most of the current “literature” surrounding the presence of thrombosis in COVID-19 disease and appropriate prophylaxis/treatment modalities is certainly retrospective at best, and anecdotal at worst. But in these times of rapidly changing information and perspective, an assessment of all available...
Main Authors: | Ali Elbeddini, Rachel Gerochi, Ahmed Elshahawi |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2020-12-01
|
Series: | Journal of Pharmaceutical Policy and Practice |
Online Access: | http://dx.doi.org/10.1186/s40545-020-00274-8 |
Similar Items
-
Pharmacy response to COVID-19: lessons learnt from Canada
by: Ali Elbeddini, et al.
Published: (2020-12-01) -
Treatment of Clostridium difficile infection in community teaching hospital: a retrospective study
by: Ali Elbeddini, et al.
Published: (2021-12-01) -
COVID-19-associated coagulopathy: thromboembolism prophylaxis and poor prognosis in ICU
by: Runhui Zheng, et al.
Published: (2021-02-01) -
Characteristics and treatment of coagulopathy associated with COVID-19
by: Miljić Predrag
Published: (2021-01-01) -
COVID-19 Associated Coagulopathy and Implications for its Treatment
by: Cherneva Zh., et al.
Published: (2020-09-01)